Who is sponsoring NCT01266031?

NCT01266031 is sponsored by National Cancer Institute (NCI).

What condition does NCT01266031 study?

NCT01266031 studies Malignant Glioma, Recurrent Glioblastoma.

What drugs are being tested in NCT01266031?

Interventions: vorinostat, bevacizumab.

What is the status of NCT01266031?

NCT01266031 is currently COMPLETED.

Last reviewed 2018-07-31 · How we verify

Phase I/II Adaptive Randomized Trial of Bevacizumab Versus Bevacizumab Plus Vorinostat in Adults With Recurrent Glioblastoma

NCT01266031 PHASE1, PHASE2 COMPLETED Results posted

The goal of this Phase I portion of this clinical research study is to find the highest tolerable dose of bevacizumab with or without vorinostat, that can be given to patients with malignant gliomas. The safety of these drug combinations will also be studied. The goal of this Phase II part of this clinical research study is to learn if bevacizumab when given with or without vorinostat can help to control malignant gliomas. The safety of these drug combinations will also be studied.

Details

Lead sponsor	National Cancer Institute (NCI)
Phase	PHASE1, PHASE2
Status	COMPLETED
Enrolment	96
Start date	Tue Jul 12 2011 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Tue Jan 31 2017 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

Malignant Glioma
Recurrent Glioblastoma

Interventions

vorinostat
bevacizumab

Countries

United States